Drug Profile


Alternative Names: Cosopt; Cosopt Mini; Cosopt PF; L-671152/timolol; MK-507/timolol

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Akorn; Merck & Co; Merck Sharp & Dohme; Purdue Pharma; Santen Pharmaceutical; Sidus
  • Class Antiglaucomas; Propanolamines; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 09 Dec 2015 COSOPT® licensed to Purdue Pharma in Canada
  • 10 Mar 2015 Japanese Ministry of Health, Labour and Welfare approves a preservative free formulation of dorzolamide/timolol for treatment of Glaucoma and Ocular hypertension in Japan
  • 15 Aug 2014 Santen Pharmaceutical files for approval of a preservative-free formulation of Dorzolamide/timolol in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top